To Get Help Now
Click Here
Today's Date:

Judge Approves GlaxoSmithKline $3 billion Health Fraud Settlement

AddThis Social Bookmark Button

U.S. District Judge Rya Zobel has approved a $3 billion health fraud settlement agreement between the U.S. government and pharmaceutical giant GlaxoSmithKline for civil and criminal violations after the company pleaded guilty to promoting drugs for unapproved uses and failing to report safety problems with certain drugs to the government. The settlement resolves allegations involving ten drugs.

GlaxoSmithKline plead guilty to promoting the antidepressant Paxil as safe for adolescents and children, though it was not approved for use in those age groups, and clinical trials showed a possible increased suicide risk. The company also admitted guilt in promoting Wellbutrin for off-label uses including as a treatment for bipolar disorder, anxiety, attention deficit disorder, obesity, and sexual dysfunction, though the drug was never proved to be an effective or safe treatment for those conditions.

GSK admitted that it did not report some safety issues with Avandia to the government, and the diabetes drug was later found to significantly increase the risk of heart failure and heart attack.

GlaxoSmithKline Chief Executive Officer Andrew Witty said in a statement, “Whilst these originate in a different era for the company, they cannot and will not be ignored. On behalf of GSK, I want to express our regret and reiterate that we have learned from the mistakes that were made.” disclaimer: This article: Judge Approves GlaxoSmithKline $3 billion Health Fraud Settlement was posted on Friday, July 6th, 2012 at 7:39 pm at and is filed under Defective Drug Lawsuits.

« »

Comments are closed.